Emerging blood exosome-based biomarkers for preclinical and clinical Alzheimer 's disease: a meta-analysis and systematic review
Wei-Lin Liu1
Hua-Wei Lin2
Miao-Ran Lin3
Yan Yu3
Huan-Huan Liu2
Ya-Ling Dai3
Le-Wen Chen2
Wei-Wei Jia3
Xiao-Jun He2
Xiao-Ling Li3
Jing-Fang Zhu3
Xie-Hua Xue4
Jing Tao2
Li-Dian Chen2
1.Academy of Rehabilitation Industry,Fujian University of Traditional Chinese Medicine,Fuzhou,Fujian Province,China;Department of Biochemistry and Molecular Biology,University of Oklahoma Health Sciences Center,Oklahoma City,OK,USA2.Academy of Rehabilitation Industry,Fujian University of Traditional Chinese Medicine,Fuzhou,Fujian Province,China3.National-Local Joint Engineering Research Center of Rehabilitation Medicine Technology,Fujian University of Traditional Chinese Medicine,Fuzhou,Fujian Province,China4.Affiliated Rehabilitation Hospital of Fujian University of Traditional Chinese Medicine,Fuzhou,Fujian Province,China
摘要：Blood exosomes, which are extracellular vesicles secreted by living cells into the circulating blood, are regarded as a relatively noninvasive novel tool for monitoring brain physiology and disease states. An increasing number of blood cargo-loaded exosomes are emerging as potential biomarkers for preclinical and clinical Alzheimer's disease. Therefore, we conducted a meta-analysis and systematic review of molecular biomarkers derived from blood exosomes to comprehensively analyze their diagnostic performance in preclinical Alzheimer's disease, mild cognitive impairment, and Alzheimer's disease. We performed a literature search in PubMed, Web of Science, Embase, and Cochrane Library from their inception to August 15, 2020. The research subjects mainly included Alzheimer's disease, mild cognitive impairment, and preclinical Alzheimer's disease. We identified 34 observational studies, of which 15 were included in the quantitative analysis (Newcastle-Ottawa Scale score 5.87 points) and 19 were used in the qualitative analysis. The meta-analysis results showed that core biomarkers including Aβ1–42, P-T181-tau, P-S396-tau, and T-tau were increased in blood neuron- derived exosomes of preclinical Alzheimer's disease, mild cognitive impairment, and Alzheimer's disease patients. Molecules related to additional risk factors that are involved in neuroinflammation (C1q), metabolism disorder (P-S312-IRS-1), neurotrophic deficiency (HGF), vascular injury (VEGF-D), and autophagy-lysosomal system dysfunction (cathepsin D) were also increased. At the gene level, the differential expression of transcription-related factors (REST) and microRNAs (miR-132) also affects RNA splicing, transport, and translation. These pathological changes contribute to neural loss and synaptic dysfunction. The data confirm that the above-mentioned core molecules and additional risk-related factors in blood exosomes can serve as candidate biomarkers for preclinical and clinical Alzheimer's disease. These findings support further development of exosome biomarkers for a clinical blood test for Alzheimer's disease. This meta-analysis was registered at the International Prospective Register of Systematic Reviews (Registration No. CRD4200173498, 28/04/2020).
机标关键词：meta-analysisalzheimerreviewbloodbiomarkersdiseaseemergingexosome-based
论文发表日期：2022-11-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：10( 2381-2390 )
英文信息